EDIT - Editas Medicine, Inc.
| Previous Close | 24.74 |
| Open | 24.63 |
| Bid | 23.91 x 1100 |
| Ask | 24.01 x 1800 |
| Day's Range | 23.71 - 24.68 |
| 52 Week Range | 17.80 - 41.43 |
| Volume | 166,678 |
| Avg. Volume | 1,055,618 |
| Market Cap | 1.174B |
| Beta (3Y Monthly) | 2.50 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -2.34 |
| Earnings Date | May 1, 2019 - May 6, 2019 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 46.71 |
- InvestorPlace•yesterday
Should You Buy Bio-Path Stock After 5-Fold Gain? 3 Pros, 3 Cons
With so much attention pointing once again to the again-escalating U.S.-China trade dispute, it's easy to overlook Bio-Path Holdings (NASDAQ:BPTH). However, the oncology specialist is easily one of the best-performing investments of 2019. Year-to-date, BPTH stock has gained a mind-blowing near-500%.More importantly, a fundamental catalyst supports the dramatic rise in valuation. A favorable clinical trial of the company's acute myeloid leukemia drug lifted Bio-Path stock from the doldrums. This news has obvious positive implications, as this particular cancer has a market size of $701.6 million. Overall, leukemia's market value will likely hit $12 billion in a few years.At the same time, biotechnology firms are hardly stable investments. While BPTH stock currently enjoys the afterglow of a promising trial, it could just as easily go awry. After all, if cancer research was straightforward, we'd already have a cure.InvestorPlace - Stock Market News, Stock Advice & Trading TipsInvariably, though, the skyrocketing Bio-Path stock commands our attention. Should you buy into this winning streak, or is this hand destined to cool? Here are three pros and three cons to consider: Pro 1: A Possible Breakthrough Could Further Boost BPTH StockI'm not breaking new ground when I say that cancer is an uncomfortable subject. However, acute myeloid leukemia is a nasty strain. The disease spreads very rapidly if left untreated. By entering the bloodstream, this cancer can affect the liver, spleen, central nervous system, and testicles. * Top 7 Service Sector Stocks That Will Pay You to Own Them The latter may have caught the attention of Wall Street's men, who fueled the spike in BPTH stock.In all seriousness, though, the latest clinical trial offered encouraging data. Out of 17 patients in the study, 11 responded to Bio-Path's prexigebersen drug. And of those 11, five experienced a complete response. Pro 2: Bio-Path Stock Levers Profound TechnologiesA thousand years from now, I'm sure that our future progeny will look back on us with macabre fascination for how we treated cancer by blasting patients with radiation. I can't help but bring up the obvious question: doesn't radiation cause cancer?Fortunately, much smarter people than I have answered this inquiry. Bio-Path's solution is their proprietary DNAbilize platform. In short, this enables oncologists to precisely deliver cancer-killing therapies to affected cells without nuking the patient.Such technologies lever a broader impact on this industry. Some patients simply don't have the physical strength to endure chemotherapy or radiology. DNAbilize is a lifesaver on multiple fronts, further bolstering the case for Bio-Path stock. Pro 3: BPTH Probably Already Hit Rock-BottomI'm not always comfortable with the argument that a particular stock has priced in all the bad news. Unless you're privy to insider information -- at which point you shouldn't act on that info -- you just don't know if more nasty stuff lies ahead.However, I can't imagine BPTH stock falling even more than it already has. Bear in mind that shares used to trade for well over $500 just a few years ago. With that context, BPTH appears like a bargain, even with this year's mooning. Con 1: Shares Used to Trade at $500-plusOn one hand, the ability to buy Bio-Path stock for pennies on the dollar appeals to many contrarians. But those with a critical eye will argue that a reason exists for the meltdown.Let's look even further back. In early January 2014, BPTH stock was on the cusp of clearing $1,000. In May of 2008, and just prior to the Great Recession, it hit four digits.The argument that "it can't get any worse" failed these early investors "bigly." You don't want to repeat their mistake. Con 2: Bio-Path has Tough CompetitionWhile Bio-Path's DNAbilize platform appears profoundly impressive, it's not the only party in town. BPTH is riding the broader category of gene therapy, or the targeted delivery of disease-fighting therapies. But other names, including CRISPR Therapeutics (NASDAQ:CRSP), Roche Holding (OTCMKTS:RHHBY), and Editas Medicine (NASDAQ:EDIT) compete aggressively in this sector. * 5 Cloud Stocks to Help Your Portfolio Fly Given the historical volatility in BPTH stock, I want some reassuring factors that I can depend on. Unfortunately, Bio-Path doesn't have a moat, which makes me jittery about its sudden rise. Con 3: Biotech is Incredibly VolatileRight now, everyone has mad love for Bio-Path stock because of its unexpected ascent. However, I've seen this story play out before in this wild market segment. All it takes is one bad trial to undo years of effort and research.Plus, BPTH stock has two obstacles regarding its drug pipeline. Management must demonstrate that their therapies can consistently beat placebo, which is no easy task. Plus, they have to show that their solutions are superior to the competition. Again, that's no gimme. Bottom Line on BPTH StockAdmittedly, I see the both the technical and fundamental potential for BPTH, and I'm personally intrigued. However, I keep going back to the inherent volatility of the biotech industry and Bio-Path stock. Yes, it enjoyed a positive paradigm-shift, but it could just as easily go sour.As of this writing, Josh Enomoto did not hold a position in any of the aforementioned securities. More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * 7 Invincible Stocks Leading The Bull Market Higher * 5 Dow Jones Stocks Coming to Life * 7 of the Best High-Yield Funds for 2019 and Beyond Compare Brokers The post Should You Buy Bio-Path Stock After 5-Fold Gain? 3 Pros, 3 Cons appeared first on InvestorPlace.
- Simply Wall St.•4 days ago
What Do Investors Need To Know About Editas Medicine, Inc.’s (NASDAQ:EDIT) Earnings Outlook?
The latest earnings release Editas Medicine, Inc.'s (NASDAQ:EDIT) announced in December 2018 showed that losses became smaller relative to the prior year's level as a result of recent tailwinds BelowRead More...
- Motley Fool•10 days ago
3 Stocks That Could Double Your Money
Here's why Wall Street thinks these stocks could generate returns of 100% or more in the next 12 months.
- Motley Fool•15 days ago
5 Top Gene-Editing Stocks for 2019
The future of treating disease might be gene editing, and these five stocks have the most promising technologies.
- Thomson Reuters StreetEvents•18 days ago
Edited Transcript of EDIT earnings conference call or presentation 28-Feb-19 10:00pm GMT
Q4 2018 Editas Medicine Inc Earnings Call
- Zacks•18 days ago
S&P Reclaims 2800; NASDAQ’s Streak Hits 10 Weeks
S&P; Reclaims 2800; NASDAQ’s Streak Hits 10 Weeks
- Motley Fool•21 days ago
Why Editas Medicine Stock Soared Today
The genome-editing leader just delivered an exciting quarterly update.
- ETF Trends•21 days ago
A Specialty Biotech ETF Strengthens on Optimism Over CRISPR Advancements
A targeted biotechnology ETF strategy jumped Friday after Editas Medicine (NasdaqGS: EDIT) announced fourth quarter results, revealing its latest progress toward the commercialization of its EDIT-101 drug ...
- Motley Fool•21 days ago
Editas Medicine Prepares to Make History With EDIT-101
After another solid quarter of progress, the genome-editing company looks forward to a phase 1/2 study for its revolutionary CRISPR medicine.
Motley Fool•21 days agoEditas Medicine Inc (EDIT) Q4 2018 Earnings Conference Call Transcript
EDIT earnings call for the period ending December 31, 2018.
- GlobeNewswire•22 days ago
Editas Medicine Announces Fourth Quarter and Full Year 2018 Results and Update
EDIT-101 for LCA10 set to be first ever in vivo CRISPR medicine administered to patients with dosing expected in second half of 2019 Advancing potentially best-in-class.
- GlobeNewswire•22 days ago
Editas Medicine Supports Global Movement to Raise Awareness on Rare Disease Day®
Editas Medicine, Inc. (EDIT), a leading genome editing company, announced today the Company is joining forces with the nearly 30 million Americans living with a rare disease and health care advocates around the world to help elevate awareness of rare diseases for Rare Disease Day®. There are more than 7,000 rare diseases impacting people around the world and approximately 90 percent of these diseases are still without FDA-approved medical treatments. “At Editas Medicine, we are making significant progress towards developing transformative genome editing medicines for people living with serious diseases, including rare genetic diseases,” said Tim Hunt, Senior Vice President, Corporate Affairs, Editas Medicine.
- Zacks•23 days ago
The Zacks Analyst Blog Highlights: Spark Therapeutics, Solid Biosciences, REGENXBIO, Editas Medicine and uniQure
The Zacks Analyst Blog Highlights: Spark Therapeutics, Solid Biosciences, REGENXBIO, Editas Medicine and uniQure
- Zacks•23 days ago
Editas (EDIT) to Report Q4 Earnings: What's in the Cards?
Focus of Editas' (EDIT) fourth-quarter conference call is likely to be on its pipeline.
- Zacks•24 days ago
CRISPR Therapeutics Up as Dosing Starts in Thalassemia Study
CRISPR Therapeutics (CRSP) and partner Vertex start dosing of beta thalassemia patients in an early-stage study evaluating gene editing therapy, CTX001. Initiates enrollment in sickle cell disease study.
- Zacks•24 days ago
5 Gene Therapy Stocks to Enrich Your Portfolio
Gene therapy stocks have not only soared on Roche-Spark deal news but are also poised to make the most of the next gene revolution.
- Motley Fool•26 days ago
Better Buy: Editas Medicine vs. Intellia Therapeutics
Which stock wins in a matchup between two leading gene-editing biotechs?
- GlobeNewswire•29 days ago
Editas Medicine to Host Conference Call Discussing Fourth Quarter and Full Year 2018 Corporate Update and Results
CAMBRIDGE, Mass., Feb. 21, 2019 -- Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, today announced that it will host a conference call and webcast on.
- Zacks•last month
Editas Medicine (EDIT) Dips More Than Broader Markets: What You Should Know
Editas Medicine (EDIT) closed the most recent trading day at $19.86, moving -0.45% from the previous trading session.
- Motley Fool•last month
Is Moderna a Buy?
The biggest-ever biotech IPO heralds enormous promise for a new class of medicines.
- Motley Fool•last month
Should Sangamo's Failure Make CRISPR Investors Nervous?
The latest gene therapy to flop in a clinical trial pulled CRISPR stocks down with it.
- Zacks•last month
Editas Medicine (EDIT) Outpaces Stock Market Gains: What You Should Know
In the latest trading session, Editas Medicine (EDIT) closed at $19.75, marking a +1.65% move from the previous day.
- GlobeNewswire•last month
Editas Medicine Names David Scadden, M.D., to Board of Directors
Editas Medicine, Inc. (EDIT), a leading genome editing company, today announced that it has appointed David T. Scadden, M.D., to its Board of Directors, effective immediately. Dr. Scadden is a hematologist/oncologist and an expert on the medical applications of stem cell biology with a particular emphasis on its use in the settings of cancer and AIDS.
- Zacks•2 months ago
Editas Medicine (EDIT) Stock Sinks As Market Gains: What You Should Know
In the latest trading session, Editas Medicine (EDIT) closed at $21.60, marking a -0.6% move from the previous day.
- InvestorPlace•2 months ago
3 Biotech Stocks That Are Set for a Breakthrough
The future of medicine is all about the personalization of medicine. That means doctors will be able to tailor treatments that fit your specific ailments. Not the general ailments of a large population of people. Today, medicine is designed to treat the most common symptoms of a disease. So everyone with that same disease will be given the exact same treatment. But considering we all have different genetic makeups, this method is clearly not ideal. That is where gene editing -- the ability to edit a human's genome -- comes into play. InvestorPlace - Stock Market News, Stock Advice & Trading Tips The term "gene editing" oftentimes has a negative connotation. And given some of the post-apocalyptic movies that have become popular over the years, I can understand why some people are afraid. But genetic editing has so much to offer to the future of medicine. A couple of months ago, a Chinese scientist performed the first gene edit on a human by removing the gene that causes HIV in several newborns. The scientific community was not happy as most believe the science is not far enough along to verify its safety. However, the scientist proved that gene editing does have a place in the healthcare of tomorrow. There are currently more than 10,000 known monogenic diseases that do not have a cure. A monogenic disease is caused by the mutation of one gene. Yes, one single gene. Imagine being able to repair that gene and cure a disease immediately. That's exactly what science is working toward. Sickle cell disease is one of the terrible ailments that falls into this category. Today, those with this disease live with ongoing pain and the knowledge that their life will likely be shortened. But soon, science will be able to cure these people with a single procedure. * 10 Cold Weather Stocks to Heat Up Your Returns Imagine the diseases that could be irradiated through the practice of gene editing. There are many companies working toward this goal, and today I'd like to introduce you to three of the major biotech stocks to buy that focus on gene editing. Source: Shutterstock ### Crispr Therapeutics (CRSP) Crispr Therapeutics AG (NASDAQ:CRSP) is the largest of the Big Three gene-editing biotech stocks, and it has a slight lead in the race. The company made headlines in October when the Food and Drug Administration removed its clinical hold on CTX001, Crispr's gene therapy to treat sickle cell disease. Then, on Jan. 4, the FDA granted the therapy Fast Track status. This is extremely important because it allows for more frequent interaction with the FDA review team as well as a rolling review of the marketing application. Crispr Therapeutics is backed by some powerful pharma partners. Combine that with the promising treatments making headway in the United States and Europe and it is clear that this company is a great place to start investing in this innovative and inspiring trend that should make investors a lot of money. Source: Shutterstock ### Editas Medicine (EDIT) Editas Medicine (NASDAQ:EDIT) falls in the middle of the Big Three gene-editing biotech stocks to buy. It can trace its roots back to the biggest players in the industry, specifically Feng Zhang, whose affiliation with the Broad Institute has given Editas a significant leg up. The Broad Institute owns the patents to use Crispr technology in eukaryotic cells -- more complex cells that have a nucleus where the genetic material is found -- so it puts Editas in an enviable position since it has the exclusive rights to the patents for any genetic target it chooses. * 10 High-Yield Monthly Dividend Stocks This company's promising pipeline and connections make me confident that it is one of the key stocks to buy for investors interested in profiting from gene editing over the long term. Source: Pixelbay (Modified) ### Intellia (NTLA) Intellia Therapeutics (NASDAQ:NTLA) doesn't get the same amount of press as its fellow gene-editing stocks. It is also the smallest of the three, but its upside is just as huge as the other stocks to buy on this list. I say that because Intellia stands out thanks to its proprietary lipid nanoparticle delivery (LNP) technology. This takes drug therapies directly to the genes that need to be edited and does it right there rather than having to extract the gene edit it in the lab. The process has proven to be safer and more effective than the alternatives. Intellia has many irons in the fire as well as collaborations with two successful pharmaceutical companies, and I suspect it could have several therapies in FDA trials in the coming years. The key for gene-editing stocks to buy like NTLA will be to continue their partnerships and show progress, and that's exactly what it is doing. Source: Shutterstock ### Breakthrough Stocks I want to make one final note … gene-editing stocks are what I call buried treasure stocks … you could also call them breakthrough stocks since they're under the biotech frame. That means that the big returns I believe are possible take patience and time. Most investors don't have the long-term outlook that this kind of world-changing technology requires. * The 7 Best Penny Stocks to Buy If that's you, here is my suggestion: Go out and dig a big hole in your backyard. Bury these breakthrough stocks in it, and in 10 years you can dig up your buried treasure. Metaphorically speaking, of course. Matthew McCall is the founder and president of Penn Financial Group, an investment advisory firm, as well as the editor of Investment Opportunities and Early Stage Investor. He has dedicated his career to getting investors into the world's biggest, most revolutionary trends BEFORE anyone else. The power of being "first" gave Matt's readers the chance to bank +2,438% in Stamps.com (STMP), +1,523% in Ulta Beauty (ULTA), +1,044% in Tesla (TSLA), +611% in Liquefied Natural Gas Limited (LNGLY), +324% in Bitcoin Services (BTSC), just to name a few. If you're interested in making triple-digit gains from the world's biggest investment trends BEFORE anyone else, click here to learn more about Matt McCall and his investments strategy today. ### More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * 7 of the Best Stocks to Buy for a Dovish Federal Reserve * 5 Best Fidelity ETFs for Retirement Savers * 7 Blue-Chip Stocks That Could Lead the Market Higher Compare Brokers The post 3 Biotech Stocks That Are Set for a Breakthrough appeared first on InvestorPlace.
